Does Imipenem Anhydrous Cilastatin And Relebactam Anhydrous Interact with Ganciclovir?
Imipenem Anhydrous Cilastatin And Relebactam Anhydrous and Ganciclovir have a major drug interaction according to U.S. FDA drug labeling data. 7 DRUG INTERACTIONS Ganciclovir: Avoid concomitant use. ( 7.2 ) 7.1 Ganciclovir Generalized seizures have been reported in patients who received ganciclovir concomitantly with imipenem/cilastatin, a component of RECARBRIO. Ganciclovir should not be used concomitantly with RECARBRIO unless the potential benefits outweigh the risks. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Imipenem Anhydrous Cilastatin And Relebactam Anhydrous Class
- Renal Dehydropeptidase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
What To Tell Your Doctor or Pharmacist
If you are taking Imipenem Anhydrous Cilastatin And Relebactam Anhydrous and your doctor is considering prescribing Ganciclovir (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider